安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- About Us - RAPT Therapeutics
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologic diseases Utilizing our deep and proprietary expertise in immunology, we develop novel molecules that are designed to modulate the critical immune responses underlying these diseases Our
- Homepage - RAPT Therapeutics
RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases Our cutting-edge science is fully focused on developing therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammatory and immunologic diseases, and improve and empower countless lives Join us in our quest
- Science - RAPT Therapeutics
THE CUTTING-EDGE SCIENCE TO TARGET CRUCIAL DRIVERS OF INFLAMMATION Our proprietary drug discovery and development engine has identified several immune drivers that have the ability to be “tuned up” or “tuned down” to modulate the immune system, either to suppress an overactive immune response in allergic inflammatory diseases or to initiate an immune response against cancer
- RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1 2 . . .
RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial . . .
About RAPT Therapeutics, Inc RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology
- RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial . . .
RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively RAPT is also pursuing a range of targets that are in the discovery stage of development Forward-Looking Statements
- RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce . . .
RAPT Forward-Looking Statements This press release contains forward-looking statements These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or
- RAPT Therapeutics to Report Promising Preclinical Studies Supporting . . .
RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively The Company is also pursuing a range of targets that are in the discovery stage of development
|
|
|